Literature DB >> 19813777

Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective, 'real-world' comparison with amlodipine.

Masahiro Ohta1, Shinichi Sugawara, Noriyuki Sato, Chizuko Kuriyama, Chisho Hoshino, Akio Kikuchi.   

Abstract

BACKGROUND AND
OBJECTIVE: Calcium channel antagonists (calcium channel blockers [CCBs]) are often used in the treatment of patients with hypertension to achieve strict blood pressure (BP) targets. In the present study, we compared the antihypertensive effects (determined by home BP [HBP] measurements) and the effects on renal function of benidipine (hydrochloride) and amlodipine (mesylate), a commonly used CCB.
METHODS: Changes in HBP and urinary albumin excretion (UAE) were investigated in 47 benidipine and 37 amlodipine recipients with essential hypertension and albuminuria between January 2007 and December 2007. Both benidipine and amlodipine significantly reduced morning and evening HBP over a 12-month period.
RESULTS: Both medications also significantly reduced UAE compared with pretreatment values; however, the reduction in UAE observed in the benidipine group occurred independent of the drug's antihypertensive effects, whereas a positive correlation was shown between the reduction in morning systolic BP and UAE in the amlodipine group.
CONCLUSIONS: These results demonstrate that benidipine favourably affects renal function in patients with essential hypertension compared with amlodipine, suggesting that the clinical benefits of benidipine as an antihypertensive drug include a renoprotective effect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19813777     DOI: 10.2165/11320000-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  23 in total

1.  Decrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats.

Authors:  M Okumura; M Masada; Y Yoshida; H Shintaku; M Hosoi; N Okada; Y Konishi; T Morikawa; K Miura; M Imanishi
Journal:  Kidney Int       Date:  2006-06-14       Impact factor: 10.612

Review 2.  Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker.

Authors:  Kozo Yao; Ken Nagashima; Hiroyuki Miki
Journal:  J Pharmacol Sci       Date:  2006-03-25       Impact factor: 3.337

3.  The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements.

Authors:  Kyuzi Kamoi; Tomoo Ikarashi
Journal:  Clin Exp Hypertens       Date:  2005-05       Impact factor: 1.749

4.  Benidipine dilates both pre- and post-glomerular arteriole in the canine kidney.

Authors:  W Yue; S Kimura; Y Fujisawa; R Tian; F Li; M Rahman; A Nishiyama; T Fukui; Y Abe
Journal:  Hypertens Res       Date:  2001-07       Impact factor: 3.872

5.  Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients.

Authors:  Kyuzi Kamoi; Masashi Miyakoshi; Satoshi Soda; Susumu Kaneko; Osamu Nakagawa
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

6.  Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats.

Authors:  T Kawata; S Hashimoto; T Koike
Journal:  J Cardiovasc Pharmacol       Date:  1997-10       Impact factor: 3.105

Review 7.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.

Authors:  J C Peterson; S Adler; J M Burkart; T Greene; L A Hebert; L G Hunsicker; A J King; S Klahr; S G Massry; J L Seifter
Journal:  Ann Intern Med       Date:  1995-11-15       Impact factor: 25.391

10.  Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.

Authors:  Osamu Akizuki; Atsushi Inayoshi; Tetsuya Kitayama; Kozo Yao; Shiro Shirakura; Katsutoshi Sasaki; Hideaki Kusaka; Masahiro Matsubara
Journal:  Eur J Pharmacol       Date:  2008-02-12       Impact factor: 4.432

View more
  2 in total

1.  T-type Ca(2+) channels facilitate NO-formation, vasodilatation and NO-mediated modulation of blood pressure.

Authors:  Per Svenningsen; Kenneth Andersen; Anne D Thuesen; Hee-Sup Shin; Paul M Vanhoutte; Ole Skøtt; Boye L Jensen; Caryl Hill; Pernille B L Hansen
Journal:  Pflugers Arch       Date:  2014-03-14       Impact factor: 3.657

2.  Endothelial Nitric Oxide Suppresses Action-Potential-Like Transient Spikes and Vasospasm in Small Resistance Arteries.

Authors:  Josh F Smith; Hamish A L Lemmey; Lyudmyla Borysova; C Robin Hiley; Kim A Dora; Christopher J Garland
Journal:  Hypertension       Date:  2020-07-27       Impact factor: 10.190

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.